Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other Working Capital Changes (2016 - 2025)

Syndax Pharmaceuticals has reported Other Working Capital Changes over the past 11 years, most recently at -$9.1 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$9.1 million for Q4 2025, down 188.03% from a year ago — trailing twelve months through Sep 2025 was $6.0 million (down 21.58% YoY), and the annual figure for FY2024 was $8.4 million, up 1341.57%.
  • Other Working Capital Changes for Q4 2025 was -$9.1 million at Syndax Pharmaceuticals, down from $4.4 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for SNDX hit a ceiling of $10.8 million in Q2 2025 and a floor of -$9.1 million in Q4 2025.
  • Median Other Working Capital Changes over the past 5 years was -$228000.0 (2021), compared with a mean of $455550.0.
  • Peak annual rise in Other Working Capital Changes hit 2324.54% in 2022, while the deepest fall reached 9866.23% in 2022.
  • Syndax Pharmaceuticals' Other Working Capital Changes stood at -$77000.0 in 2021, then crashed by 9866.23% to -$7.7 million in 2022, then soared by 48.44% to -$4.0 million in 2023, then grew by 19.79% to -$3.2 million in 2024, then tumbled by 188.03% to -$9.1 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$9.1 million (Q4 2025), $4.4 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.